about
Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocationDetermination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhAAn ordered water channel in Staphylococcus aureus FabI: unraveling the mechanism of substrate recognition and reduction.Structural basis and mechanism of enoyl reductase inhibition by triclosanCrystal structure of Mycobacterium tuberculosis MenB, a key enzyme in vitamin K2 biosynthesisLysine 190 is the catalytic base in MenF, the menaquinone-specific isochorismate synthase from Escherichia coli: implications for an enzyme familyStructure and mechanism of MbtI, the salicylate synthase from Mycobacterium tuberculosisSlow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo ActivityCrystal Structures of Mycobacterium tuberculosis KasA Show Mode of Action within Cell Wall Biosynthesis and its Inhibition by ThiolactomycinA Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosisStructural and Functional Studies of Fatty Acyl Adenylate Ligases from E. coli and L. pneumophilaMechanism of the Intramolecular Claisen Condensation Reaction Catalyzed by MenB, a Crotonase Superfamily MemberStructure of the Yersinia pestis FabV Enoyl-ACP Reductase and Its Interaction with Two 2-Pyridone InhibitorsRational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product ComplexStaphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo EssentialityStructural Basis for the Recognition of Mycolic Acid Precursors by KasA, a Condensing Enzyme and Drug Target from Mycobacterium TuberculosisA structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA.Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo EfficacyRational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase InhibitorA machine learning-based method to improve docking scoring functions and its application to drug repurposingA Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis PathwayDrug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosisMechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureusMechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesisMechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia malleiUltrafast Electronic and Vibrational Dynamics of Stabilized A State Mutants of the Green Fluorescent Protein (GFP): Snipping the Proton WireUltrafast structural dynamics in BLUF domains: transient infrared spectroscopy of AppA and its mutants.Ultrafast Structural Dynamics of BlsA, a Photoreceptor from the Pathogenic Bacterium Acinetobacter baumannii.Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitorsInhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.A novel interaction linking the FAS-II and phthiocerol dimycocerosate (PDIM) biosynthetic pathways.A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacyNovel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboonsRational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA.Drug-target residence time: critical information for lead optimization.Resonance Raman spectroscopic and kinetic consequences of a nitrogen ... sulphur enzyme-substrate contact in a series of dithioacylpapains.Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei
P50
Q24603577-7821D6DF-EB3D-43BA-B519-058E7C45E6FDQ27324299-A339D6D0-2C10-4628-B1B1-9ECC7EEBBF68Q27339306-BE077AFB-932B-4FD7-BC41-D66BA8E891ABQ27339591-33AD8B56-ABD7-4988-8DCD-7CE627EEF3FCQ27618977-4D0DEB46-A3DE-424E-9691-A382E06E911AQ27641816-36B87117-6180-4E07-9662-B328ED0805FEQ27643604-B8BBD3F6-6996-4C3C-9A00-55A0E411F610Q27643605-F6A7CB47-5C5A-495A-8A1A-67E0ED70EF02Q27653711-5AE03FE4-3695-4207-A6D0-C5E34483A2EBQ27656454-53A63183-650F-4399-A7EF-55EDE655CA52Q27660104-9C79452D-C321-4CD1-A700-7474021133B7Q27666389-9223F2C3-5BEE-49AC-AE05-0A96E266D45BQ27671659-E584417F-7388-4A7A-83E2-751673BAB7DBQ27676726-9DAB651E-D80A-477E-9A8E-1F71B52719D6Q27678258-08D0DAC3-7B5C-4BA3-B809-791AD89D9279Q27679034-0BC26C5E-950E-4108-85CA-79E59CD182E0Q27680210-71373A14-AB10-4698-8374-A1883A7E9C8EQ27681724-AAB0B2F1-3157-4ED0-B694-D5F85367FDFFQ27682088-096C17B7-B67D-4CBD-98B3-D613BE2540F2Q27683440-2390364E-6C25-4977-9A94-2280E160FA0CQ28304560-81AED835-4E9E-4D7E-A585-24815FBF2A44Q28396297-6EBC0045-E97E-4C42-999E-CBB365325E39Q28475676-122D0155-F97C-4411-97F5-ABD62C2B3C94Q28485592-4B6926B1-291E-4299-BB5E-463386099A19Q28486730-679AEBC4-F01F-431B-9D87-4F33477B620FQ28492113-17D87BC7-D7E7-4483-BAD6-4D5D5C405DB6Q30378415-DCB354B0-8B09-42B5-B0F9-82F150B737BDQ31137387-817ADCAA-A25D-4987-9D4A-E11B8B208962Q31158428-3EA10AAA-3038-4FC0-88ED-249BC44D5F29Q33289279-CAA5092A-2EC2-450A-A8BE-D20574BDFAC3Q33292548-21DC06A9-46F7-40F0-848F-7ACE00C1596EQ33314589-C8549986-F392-4DC1-BF12-879D7B875F10Q33360202-207B6D1E-0162-4E00-A030-293A7659E642Q33636442-D18D85A2-EB07-42CD-8632-0B9A887DBBA1Q33761632-BF274DE5-E8D4-4F60-9F05-F58EE1464094Q33835981-A420FE1B-8FB8-444B-A4F3-081839F86BEFQ34044404-D8BD44EF-D601-481A-9E6E-9C3C093C4FD2Q34054343-6DB161A9-504F-42F5-B81B-8DE5EEF9DF7DQ34091486-0FEDB0D4-E201-4782-B71B-3C444A768522Q34566539-141B1F4A-D525-4DC4-A088-19367DB65D20
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter J Tonge
@nl
Peter J Tonge
@sl
Peter J. Tonge
@en
Peter J. Tonge
@es
type
label
Peter J Tonge
@nl
Peter J Tonge
@sl
Peter J. Tonge
@en
Peter J. Tonge
@es
prefLabel
Peter J Tonge
@nl
Peter J Tonge
@sl
Peter J. Tonge
@en
Peter J. Tonge
@es
P106
P1153
7003501916
P21
P2456
P31
P496
0000-0003-1606-3471